Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 1998

View Archived Issues

Genzyme General expands cardiovascular gene therapy program

AltaRex: Q1 1998 highlights

Company Profile: Link Technology

DuPont Merck and Cytogen continue Quadramet collaboration

CNI-1493 prevents IL-2 toxicity without affecting antitumor activity in rats

Reduction of colon cell proliferation associated with soy product consumption

Bristol-Myers Squibb presents derivatives of indolopyrrolocarbazoles as antitumor agents

Neurokinin antagonists for bronchoconstriction, neurogenic inflammation

Biomira's lymphoma vaccine headed for phase I testing

Newly discovered toxic protein may trigger onset of Alzheimer's disease

Therapeutic Antibodies: Q1 1998 highlights

A-127722 reduces ischemic lesion size in rat model of focal cerebral ischemia

KCB-328: electrophysiological effects of novel class III antiarrhythmic

Techniclone restructures TNT development joint venture

New antiplatelet agents prepared by Sankyo/Ube researchers

Optison launched in Europe

New tachykinin antagonists patented by Pfizer

Preparation and use of MMP/TNF production inhibitors described by Pfizer

Final results of ECST presented

Avonex now available in Canada

New 5-HT2C antagonists presented by Syntex

EP3-selective prostanoid from Ono affords cardioprotection in rabbit MI model

New antiepileptic compounds described by Portela

Matrix receives patent protection for MPI-5020 and AccuSite

Early- and late-phase cardioprotective effects demonstrated for OPC-6535 in pig model

Review study finds mesalamine most effective treatment for ulcerative colitis

Aphton describes efficacy of Gastrimmune at two major scientific meetings

FDA advisory committee recommends approval of Avakine for Crohn's disease

Somatostatin analogue TT-232 prevents proliferation of pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...